European Companies Search Engine
Member of the Executive Board (1) · Capital: €352,493 · Company statute Hrb22 Jun 2007 German Trade Register Announcements, Germany (15/06/2007)
Overview
Text
Ganymed Pharmaceuticals AG, Mainz (
Unnamed street ??, 55131 Mainz, Germany
). Appointed as a further member of the Board of Directors: Prof. Dr. ?????, ????, Mainz, *??.??.????. The Annual General Meeting of April 12, 2007 decided to increase the share capital by EUR 94,052.00 to EUR 352,493.00. The increase in the share capital has been carried out. The Annual General Meeting of April 12, 2007 also approved the amendment of the Articles of Association in Section 3 (Fiscal Year), Section 4 (Share Capital), Section 5 (Preferred Shares), Section 10 (General), Section 14 (Decisions), Section 17 (Convening), and Section 19 (Shareholders' Resolutions). With the approval of the Supervisory Board, the Management Board is authorized to increase the share capital by up to a total of EUR 165,433.00 against cash contribution (authorized capital I) by December 31, 2010. The share capital is conditionally increased by EUR 77,846.00 (conditional capital V) and also increased by up to EUR 5,412.00 (conditional capital IV). The corresponding amendments in Section 4 (share capital) of the Articles of Association were adopted at the Annual General Meeting on April 12, 2007. Announced as unregistered: The share capital is now divided into 50,000 ordinary shares, 75,719 preferred shares series -A, 132,722 preferred shares Series B and 94,052 preference shares series -C, each a.s. no-par value shares.
This filing was translated from German to English. The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Ganymed Pharmaceuticals GmbH, Mainz, Germany.
The visualizations for "Ganymed Pharmaceuticals AG - Member of the Executive Board (1) · Capital: €352,493 · Company statute"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
